Preview

Клиницист

Расширенный поиск

Роль новых цитокинов : ростового фактора дифференцировки 15 (GDF-15) и хрящевого гликопротеина 39 (YKL-40) в развитии и прогрессировании атеросклероза коронарных артерий

https://doi.org/10.17650/1818-8338-2012-6-3-4-

Полный текст:

Аннотация

В обзоре представлены новые данные по изучению неспецифических биомаркеров, относящихся к семейству цитокинов: хрящевого гликопротеина 39 и ростового фактора дифференцировки 15, при коронарном атеросклерозе.

Об авторах

М. В. Ежов
ФГБУ «Российский кардиологический научно-производственный комплекс» Минздрава России
Россия
Отдел проблем атеросклероза Института клинической кардиологии им. А.Л. Мясникова


Т. Ю. Полевая
ФГБУ «Российский кардиологический научно-производственный комплекс» Минздрава России
Россия
Отдел проблем атеросклероза Института клинической кардиологии им. А.Л. Мясникова


Ю. Г. Матчин
ФГБУ «Российский кардиологический научно-производственный комплекс» Минздрава России
Россия
Отдел проблем атеросклероза Института клинической кардиологии им. А.Л. Мясникова


Список литературы

1. Чазов Е.И. Пути снижения смертности от сердечно-сосудистых заболеваний. Тер архив 2008;8:11–6.

2. Демографический ежегодник России. 2010: Статистический сборник. М.: Госкомстат России, 2010.

3. Bui Q.T., Prempeh M., Wilensky R.L. Atherosclerotic plaque development. Int J Biochem Cell Biol 2009;41(11):2109–13.

4. Chhatriwalla A.K., Nicholls S.J., Wang T.H. et al. Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol 2009;53(13):1110–5.

5. Liang K.W., Lee W.J., Lee W.L. et al. Diabetes exacerbates angiographic coronary lesion progression in subjects with metabolic syndrome independent of CRP levels. Clin Chim Acta 2008;388(1–2):41–5.

6. Zouridakis E., Avanzas P., Arroyo-Espliguero R. et al. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004;110(13):1747–53.

7. Herrmann J., Lerman L.O., Mukhopadhyay D. et al. Angiogenesis in atherogenesis. Arterioscler Thromb Vasc Biol 2006;26(9):1948–57.

8. Moreno P.R. Atherothrombosis: the global approach for a global disease. Pathophysiology of atherothrombosis. Highlights monograph from an International expert meeting on atherombosis. Milan, 1998.

9. Shah P.K. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003;41(4 Suppl S):15S–22S.

10. Agrotis A., Kalinina N., Bobik A. Transforming growth factor-beta, cell signaling and cardiovascular disorders. Curr Vasc Pharmacol 2005;3(1):55–61.

11. Белова Л.А. Биохимия процессов воспаления и поражения сосудов. Роль нейтрофилов. Биохимия 1997;62(6):659–68.

12. Johansen J.S., Jensen H.S., Price P.A. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993;32(11):949–55.

13. Rathcke C.N., Vestergaard H. YKL-40 – an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol 2009;8:61.

14. Boot R.G., van Achterberg T.A., van Aken B.E. et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion

15. macrophages. Arterioscler Thromb Vasc Biol 1999;19(3):687–94.

16. Shackelton L.M., Mann D.M., Millis A.J. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodelling. J Biol Chem 1995;270(22):13076–83.

17. Volck B., Price P.A., Johansen J.S. et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. ProcAssoc Am Physicians 1998;110(4):351–60.

18. Ringsholt M., Hogdall E.V., Johansen J.S. et al. YKL-40 protein expression in normal adult human tissues – an immunohistochemical study. J Mol Histol 2007;38(1):33–43.

19. Johansen J.S., Hoyer P.E., Larsen L.A. et al. YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem 2007;55(12):1213–28.

20. Lee C.G., Hartl D., Lee G.R. et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 2009;206(5):1149–66.

21. Fach E.M., Garulacan L.A., Gao J. et al. In vitro biomarker discovery for atherosclerosis by proteomics. Mol Cell Proteomics 2004;3(12):1200–10.

22. Rathcke C.N., Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res 2006;55(6):221–7.

23. Nishikawa K.C., Millis A.J. Gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 2003;287(1):79–87.

24. Castell J.V., Gomez-Lechon M.J., David M. et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989;242(2):237–9.

25. Johansen J.S., Pedersen A.N., Schroll M. et al. High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality. Clin Exp Immunol 2008;151(2):260–6.

26. Letuve S., Kozhich A., Arouche N. et al. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol 2008;181(7):5167–7.

27. Zheng J.L, Lu L., Hu J. et al. Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease. Atherosclerosis 2010;210(2):590–5.

28. Kucur M., Isman F.K., Karadag B. et al. Serum YKL-40 levels in patients with coronary artery disease. Coronary Artery Dis 2007;18(5):391–6.

29. Rathcke C.N., Raymond I., Kistorp C. et al. Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population. Int J Cardiol 2010;143(1):35–42.

30. Thomsen S.B., Rathcke C.N., Zerahn B., Vestergaard H. Increased levels of the calcification marker matrix Gla Protein and the inflammatory markers YKL-40 and CRP in patients with type 2 diabetes and

31. ischemic heart disease. Cardiovasc Diabetol 2010;9:86.

32. Michelsen A.E., Rathcke С.N., Skjelland M. et al. Increased YKL-40 expression in patient with carotid atherosclerosis. Atherosclerosis 2010;211(2):589–95.

33. Zimmers T., Jin X., Hsiao E. et al. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock 2005;23(6):543–8.

34. Ago T., Sadoshima J. GDF15, a cardioprotective TGF-beta superfamily protein. Circ Res 2006;98(3):294–7.

35. Argmann C.A., Van Den Diepstraten C.H., Sawyez C.G. et al. Transforming growth factor-

36. beta 1 inhibits macrophage cholesterol ester accumulation induced by native and oxidized VLDL remnants. Arterioscler Thromb Vasc Biol 2001;21(12):2011–8.

37. Anand I.S., Kempf T., Rector T.S. et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation

38. ;122(14):1387–95.

39. Bonaca M.P., Morrow D.A., Braunwald E. et al. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2011;31(1):203–10.

40. Eggers K.M., Kempf T., Allhoff T. et al. Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain. Eur Heart J 2008;29(19):2327–35.


Для цитирования:


Ежов М.В., Полевая Т.Ю., Матчин Ю.Г. Роль новых цитокинов : ростового фактора дифференцировки 15 (GDF-15) и хрящевого гликопротеина 39 (YKL-40) в развитии и прогрессировании атеросклероза коронарных артерий. Клиницист. 2012;6(3-4):17-22. https://doi.org/10.17650/1818-8338-2012-6-3-4-

For citation:


Еzhov M.V., Polevaya T.Y., Matchin Y.G. Role of the new cytokines growth differentiation factor 15 (GDF-15) and cartilage glycoprotein 39 (YKL-40) in the development and progression of coronary artery atherosclerosis. The Clinician. 2012;6(3-4):17-22. (In Russ.) https://doi.org/10.17650/1818-8338-2012-6-3-4-

Просмотров: 373


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1818-8338 (Print)
ISSN 2412-8775 (Online)